EANS-Adhoc: SYGNIS Pharma AG Genetrix Life Sciences, A.B., and Genetrix, S.L.,
Granted Exemption from Mandatory Tender Offer to Shareholders of SYGNIS Pharma AG
--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
Company Information
24.09.2012
Heidelberg, September 24,2012 - SYGNIS Pharma AG (Frankfurt: LIOK; ISIN
DE000A1E9B74; Prime Standard) was informed that the German Federal Financial
Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht; BaFin)
has granted an exemption to Genetrix Life Sciences, A.B., and to its parent
company Genetrix, S.L., from the obligation to publish the acquisition of
control over SYGNIS Pharma AG, and to provide BaFin an offer document, and to
publish a mandatory tender offer, in the event these companies will gain control
over SYGNIS Pharma AG subsequently to the resolution regarding the capital
increase against contribution in kind to be resolved on the Shareholders'
Meeting convened on October 17, 2012, coming in force.
The resolution regarding the contribution in kind by way of contributing the
shares of X-Pol Biotech, S.L., into SYGNIS Pharma AG coming in force, Genetrix
Life Sciences, A.B., and their parent company Genetrix, S.L., will acquire
control over SYGNIS Pharma AG in the meaning of Section29 (2) WpÜG and would
have been required to make a mandatory tender offer to the shareholders of
SYGNIS Pharma AG had the exemption not been granted.
**** end of ad hoc ****
For further information please contact:
SYGNIS Pharma AG
Peter Willinger
Co-CEO/CFO
Tel: +49 6221 454 836
Email: willinger@sygnis.de
### Disclaimer
This publication is intended for information only and constitutes neither an
offer to sell nor an invitation to buy securities. Some statements included in
this press release, relating neither to proven financial results nor other
historical data, should be viewed as forward-looking, i.e. not definite. Such
statements are mainly predictions of future results, trends, plans or goals.
These statements should not be considered to be total guarantees since given
their very nature they are subject to known and unknown risks and
imponderability and can be affected by other factors as a consequence of which
the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from
the established conclusions or implied predictions contained in such statements.
SYGNIS does not undertake to publicly update or revise these statements in the
light of new information or future results or for any other reason.
###
Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de
end of announcement euro adhoc
--------------------------------------------------------------------------------
issuer: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1E9B74
indexes: CDAX, Prime All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
Stuttgart, regulated dealing/prime standard: Frankfurt
language: English